PneumoNIX Medical was selected to present to Johns Hopkins Hospital, Maryland Department of Commerce and Technology Development Corporation of Maryland about their technology and its ability to increase access to lung cancer screening. The successful large-animal data which was acquired with grant funding has gathered interest from physicians and public health officials about its ability to reduce costs and complications during the lung cancer screening process. Additionally, the results have fast-tracked them for further grant funding.
top of page
Recent Posts
See AllPneumoNIX has received follow-on Phase II grant from the NSF SBIR to continue the development of their proprietary technology.
390
PneumoNIX Medical, a Baltimore-based medtech company focused on preventing complications associated with soft tissue biopsies, announced that it received Phase I SBIR grants from the NSF. The awards w
120
PneumoNIX Medical is 1 of 50 startups nationwide selected to present to the nations top angel investors. The showcase features the most promising startups from life science and technology companies. R
40
bottom of page